Initiated two Phase II trials COVALENT-211 and COVALENT-212 (icovamenib in type 2 diabetes) with 26-week primary endpoint data anticipated in the fourth quarter of 2026Completed 52-week follow-up from ...
Lab activities that practice investigation, modeling, data analysis, and design skills while learning more about animals and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results